Efficacy and safety of ixekizumab for moderate to severe psoriasis
MA Wei
LU Ying-wei
FAN Mei-na
HUA Gang
Abstract：Objective:To explore the efficacy and safety of ixekizumab for moderate to severe psoriasis.Methods:The clinical data of 76 patients with moderate to severe psoriasis who received ixekizumab treatment in our department from August 2021 to July 2023 were collected.The initial dose of Lxekizumab was subcutaneous injection at 160 mg twice.After injection,the dose was adjusted to 80 mg subcutaneously at 2,4,6,8,10,12 weeks,and finally to 80 mg for maintenance dose once every four weeks.The improvement of patients'condition before and after treatment and the occurrence of adverse reactions during the treatment were analyzed.Results:Among 76 patients with psoriasis,8 cases were positive for T-spot Test,5 cases were mild abnormal liver function,and 2 cases were mild abnormal renal function.After treatment with Lxekizumab,100%(76/76)of patients with Psoriasis Area and Severity Index(PASI)75 improved,89.5%(68/76)of patients with PASI 90 improved,and 59.2%(45/76)of patients with PASI 100 improved.The curative effect of Lxekizumab on psoriatic arthritis and psoriatic nail was remarkable.There were 8 cases of injection site swelling,2 cases of pruritus,1 case of acute pharyngitis,1 case of oral ulcer,3 cases of local eczema,1 case of pruritus erythema and 5 cases of upper respiratory tract infection.Conclusion:Ixekizumab in the treatment of moderate to severe psoriasis can get good efficacy and safety.
Keywords：IxekizumabPsoriasisAdverse reactionEfficacySafety
Publication Date：2023-10-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 356-359 )